Announced details
Regenerative medicine, mass production and stable supply of cells, drug discovery, CDMO and large-scale cell culture
Collaboration with a government institution and acceptance of an official visit. Capital, personnel and business relationships are Not disclosed.
Minister for Internal Affairs and Communications of the Japanese government. Other information on location, representative, business activities, capital and year of establishment is Not disclosed.
Kita-ku, Osaka (Nakanoshima Qross (中之島クロス))
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Nakanoshima Qross (中之島クロス), VMaCS (Value Chain Consortium for Stable Cell Supply Enabling the Development and Practical Implementation of Next-Generation Regenerative Medicine Modalities) |
| Counterparty | Minister for Internal Affairs and Communications Hayashi Yoshimasa (林芳正) |
| Counterparty overview | Minister for Internal Affairs and Communications of the Japanese government. Other information on location, representative, business activities, capital and year of establishment is Not disclosed. |
| Relationship with the Company | Collaboration with a government institution and acceptance of an official visit. Capital, personnel and business relationships are Not disclosed. |
| Launch date | June 2026 (installation of the pilot-scale plant) |
| Applicable area | Regenerative medicine, mass production and stable supply of cells, drug discovery, CDMO and large-scale cell culture |
| Location | Kita-ku, Osaka (Nakanoshima Qross (中之島クロス)) |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To deepen collaboration with the government, relevant organizations and partner companies, advance the implementation of regenerative medicine in society from Osaka and the Kansai region, and contribute to the development of healthcare and improvements in patients’ quality of life in Japan and overseas.